# A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

> **NCT01494532** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 352 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** ropinirole/L-dopa
- **DRUG:** placebo/L-dopa

## Key facts

- **NCT ID:** NCT01494532
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-02
- **Primary completion:** 2014-11-18
- **Final completion:** 2014-11-18
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01494532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01494532, "A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01494532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*